GRAIL, Inc. (GRAL) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection (MCED) via its Galleri blood test. The company operates as a standalone public entity following its spin-off from Illumina, Inc. on June 24, 2024. As of June 30, 2025, the company had 36,047,799 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenue | $35,544 | $31,970 | $67,381 | $58,691 |
| Net Loss | $(113,985) | $(1,585,337) | $(220,198) | $(1,804,251) |
| Adjusted EBITDA | $(78,322) | $(139,391) | $(177,057) | $(291,360) |
| Cash & Cash Equivalents | $127,427 | $214,234 | $127,427 | $214,234 |
| Short-term Marketable Securities | $475,327 | $549,236 | $475,327 | $549,236 |
| Total Liquidity | $602,754 | $763,470 | $602,754 | $763,470 |
| Operating Cash Flow (YTD) | $(171,977) | $(379,085) | $(171,977) | $(379,085) |
Note: Q2 2024 results include a massive non-cash goodwill and intangible impairment charge of $1.42 billion related to the spin-off accounting. Q2 2025 includes a $28 million impairment charge.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 11% in Q2 2025 and 15% YTD compared to the prior year periods. Screening revenue grew 22% in Q2 and 23% YTD, driven by a 29-30% increase in Galleri test volume, partially offset by a 5-6% decrease in average selling price (ASP).
- Expense Reduction: Operating expenses decreased significantly due to a restructuring plan implemented in late 2024.
- Research & Development (R&D) expenses dropped 51% in Q2 and 49% YTD.
- Sales & Marketing expenses dropped 30% in Q2 and 28% YTD.
- General & Administrative (G&A) expenses dropped 44% in Q2 and 33% YTD, largely due to the cessation of legal fees related to the European Commission hold-separate order and the spin-off.
- Impairment Charges: The massive $1.42 billion impairment recorded in Q2 2024 was a one-time event related to the spin-off. In Q2 2025, the company recorded a $28 million impairment charge related to its In-Process Research and Development (IPR&D) asset, writing off the remaining carrying value due to decreased projected cash flows.
- Liquidity: Total cash and short-term marketable securities decreased by approximately $160 million from the prior year period, reflecting operating cash burn, though the company maintains a strong liquidity position.
Guidance, Outlook, and Risks
- Clinical Progress: The company announced positive top-line results from the PATHFINDER 2 study (first 25,578 participants) and the prevalent screening round of the NHS-Galleri trial. Data showed substantially higher Positive Predictive Value (PPV) compared to the original PATHFINDER study.
- Regulatory Timeline: GRAIL plans to submit a Premarket Approval (PMA) application to the FDA in the first half of 2026, utilizing data from NHS-Galleri, PATHFINDER 2, and a bridging study.
- Restructuring: The restructuring plan, aimed at focusing resources on the core MCED business, was substantially completed in Q4 2024. No remaining restructuring liability exists as of June 30, 2025.
- Capital Resources: Management believes existing cash and marketable securities ($602.8 million) are sufficient to meet working capital needs for at least the next 12 months. However, the company anticipates needing to raise additional financing in the future.
- Key Risks:
- Regulatory Uncertainty: The FDA's authority over Laboratory Developed Tests (LDTs) remains in flux following a federal court vacating the LDT Final Rule in March 2025. This creates uncertainty regarding the PMA pathway.
- Reimbursement: Galleri is not currently broadly reimbursed by Medicare or large commercial insurers. Commercial success depends on securing coverage.
- Intellectual Property: The company has a royalty agreement with Illumina (high single-digit royalty) suspended until December 2026 or a change of control.
Investor Verification Checklist
- Impairment Accounting: Verify the assumptions used in the Q2 2025 IPR&D impairment test (discount rate of 21%) and confirm the write-off of the entire asset.
- Reimbursement Strategy: Assess the timeline and probability of securing Medicare coverage, given the current lack of broad reimbursement.
- Regulatory Pathway: Monitor the impact of the March 2025 federal court decision on LDTs on the company's planned H1 2026 PMA submission.
- Cash Burn Rate: Review the trajectory of operating cash burn ($172M YTD) against the current liquidity of $603M to determine the runway before additional capital raising is required.
- Volume vs. ASP: Analyze the sustainability of the 29-30% volume growth given the concurrent 5-6% decline in Average Selling Price (ASP).